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OBJECTIVES This study aimed to evaluate the relationship between anemia and heart failure (HF)
prognosis.
BACKGROUND Although it is known that chronic diseases, including HF, may be associated with anemia, the
impact of hemoglobin (Hb) level on symptoms and survival in HF has not been fully defined.
METHODS We analyzed a cohort of 1,061 patients with advanced HF (New York Heart Association
[NYHA] functional class III or IV and left ventricular ejection fraction [LVEF] 40%)
referred to a single center for evaluation and management. The Hb level was drawn at time
of initial evaluation. Patients were divided into quartiles of Hb: Hb 12.3; Hb 12.3 to 13.6;
Hb 13.7 to 14.8; Hb 14.8 g/dl.
RESULTS Mean Hb was 13.6, and values ranged from 7.1 to 19.0 g/dl. The Hb groups were similar in
age, medication profile, LVEF, hypertension, diabetes, smoking status and serum sodium.
Lower Hb was associated with an impaired hemodynamic profile, higher blood urea nitrogen
and creatinine, and lower albumin, total cholesterol and body mass index. Patients in the
lower Hb quartiles were more likely to be NYHA functional class IV (p  0.0001) and have
lower peak oxygen consumption (PKVO2) (p  0.0001). Survival at one year was higher with
increased Hb quartile (55.6%, 63.9%, 71.4% and 74.4% for quartiles 1, 2, 3 and 4,
respectively). On multivariate analysis adjusting for known HF prognostic factors, low Hb
proved to be an independent predictor of mortality (relative risk 1.131, confidence interval
1.045 to 1.224 for each decrease of 1 g/dl).
CONCLUSIONS In chronic HF, relatively mild degrees of anemia are associated with worsened symptoms,
functional status and survival. (J Am Coll Cardiol 2002;39:1780–6) © 2002 by the
American College of Cardiology Foundation
Heart failure (HF) is an increasingly important cause of
morbidity and mortality, with prevalence in the U.S. re-
cently estimated near 5 million. Although deaths from
myocardial infarction (MI) and stroke have decreased by
50% over the past decade, mortality from HF has been
steadily rising despite advances in medical and surgical
therapy (1). Identification of modifiable risk factors for HF
morbidity and mortality may lead to improvement in the
clinical management of HF.
Recent reports have suggested that mild to moderate
anemia is a prevalent condition in the HF patient popula-
tion (2,3), and severe, chronic anemia has been associated
with the de novo development of HF (4). However, the
impact of the anemic state on symptoms and prognosis in
patients with established HF has not been well-described in
the medical literature. Current guidelines and reviews do
not include anemia as a prognostic factor or treatment goal
in HF (5,6).
The effect of hemoglobin (Hb) level on HF outcomes has
been studied in certain patient populations. Anemia was a
risk factor for development of HF as well as rehospitaliza-
tion for HF in patients with end-stage renal disease
(ESRD) (7). In patients with asymptomatic left ventricular
dysfunction or mild to moderate HF, a recent analysis of
patients enrolled in the Studies Of Left Ventricular Dys-
function (SOLVD) identified low Hb as a predictor of mor-
tality independent of renal insufficiency (2). However, in HF
patients who present the most significant management chal-
lenge to physicians, those with New York Heart Association
(NYHA) functional class III and class IV, the interaction
among Hb level, symptoms and prognosis is unknown.
Recently, several small clinical studies have investigated
the correction of anemia with erythropoietin and iron as a
treatment for HF. These initial studies have shown favor-
able results including improvement in left ventricular ejec-
tion fraction (LVEF), NYHA functional class and exercise
capacity (8–10). Before larger trials are undertaken, it is
necessary to have a more complete understanding of ane-
mia’s role in the progression of advanced HF. To explore
this issue further, we examined the relationship among Hb
level, HF patient characteristics and symptoms, and HF
survival in a cohort of NYHA functional class III and class
IV HF patients of multiple etiologies.
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METHODS
Study subjects. The study subjects were 1,733 patients
referred to a single university medical center for heart
transplant evaluation between 1983 and 1999. All subjects
were followed in a comprehensive HF management pro-
gram, as previously described (11). Medical record review
was approved by the University of California-Los Angeles,
Medical Institutional Review Board. Patients with LVEF
40% (n  106), NYHA functional class 3 (n  58) and
those without an initial Hb level, “dry” weight or adequate
follow-up data (n  508) were excluded from analysis. The
final study population consisted of 1,061 subjects.
Baseline data. Both Hb and hematocrit (Hct) levels were
determined at time of initial presentation. All specimens
were analyzed in Centers for Disease Control-approved
laboratories. The NYHA functional class was assessed at the
time of initial presentation. Medical treatments recorded
were those implemented after baseline hemodynamic eval-
uation. Hemodynamic variables utilized in the analyses were
the optimal values recorded after pulmonary artery catheter-
tailored medical therapy, as these hemodynamic measure-
ments have been shown to best correlate with survival (12).
Laboratory testing, electrocardiography, echocardiography
and cardiopulmonary exercise tests all occurred within three
months of initial referral; later values were excluded from
our analysis. Creatinine clearance was calculated by the
Cockcroft-Gault formula using the patient’s “dry” weight
after hemodynamically guided therapy. Hypertension, dia-
betes and smoking histories were based on medical record
review.
End points. Death was the primary end point in this study.
Deaths were classified as sudden death, HF death or death
secondary to MI. Death was considered sudden if it was
unexpected based on the patient’s clinical status and if it
occurred out of the hospital within 15 min of the onset of
unexpected symptoms or during sleep. Death during hos-
pitalization for worsening congestive symptoms was consid-
ered an HF death. Urgent heart transplants (Status I) were
analyzed as deaths, under the assumption that these patients
would have died without a transplant. Nonurgent trans-
plants (Status II) were considered a nonfatal end of follow-
up.
Statistical analysis. Data are presented as mean  SD for
continuous variables and as frequencies for categorical
variables. Patients were divided into quartiles of Hb. Dif-
ferences in baseline characteristics among quartiles were
analyzed using analysis of variance for continuous variables
and Pearson’s chi-square test for categorical variables. To
evaluate differences between survivors and nonsurvivors, we
used an independent sample t test for continuous variables
and Pearson’s chi-square test for categorical variables. Both
one-year and five-year survival curves were calculated with
the Kaplan-Meier method, and differences between the
curves were evaluated with the log-rank statistic. We
assessed the relationship between baseline variables and
mortality using a Cox proportional hazards survival model
(SPSS for Windows, version 10.0.5). Hazard ratios (relative
risk [RR]) with 95% confidence intervals (CI) demonstrate
the risk of death when a variable is present. The multivariate
Cox model included the following variables seen to be
predictors of mortality on univariate analysis as well as other
known factors for HF mortality: age, gender, body mass
index (BMI), left ventricular end diastolic dimension, hy-
pertension history, diabetes history, smoking history, serum
sodium, albumin, creatinine and HF etiology.
RESULTS
Baseline characteristics of the cohort. The cohort was
77% male, and ages ranged from 16 to 82 years. The NYHA
functional class III and IV patients comprised 35% and 65%
of the population, respectively, and mean LVEF was 22%.
Etiologies of HF were ischemic (50%), idiopathic (38%)
and valvular (4.5%); the remaining 7.5% included alcohol-
induced, hypertrophic and postpartum cardiomyopathy.
Mean Hb was 13.6  1.9 g/dl and Hb ranged from 7.1
to 19.0 g/dl. The mean Hb level for women was 12.7 
1.8 g/dl and for men was 13.8  1.9 g/dl. Of both men and
women in the cohort, 30% were considered anemic when
anemia was defined as Hb 13 g/dl in men and Hb
12 g/dl in women (13). Hemoglobin level 17 g/dl was
seen in 3% of men and 1% of women.
Relationship between Hb level and baseline characteris-
tics. Differences among the Hb quartiles are detailed in
Table 1. Age, past medical history, LVEF, etiology of HF,
serum sodium and medication usage were similar among the
Hb groups. Patients in the lower quartiles were more likely
to be women. Lower Hb levels were associated with greater
symptoms, as evident by more patients being NYHA
functional class IV (75.3%, 68.0%, 56.7% and 59.1% for
quartiles 1, 2, 3 and 4, respectively, p  0.0001). Lower
BMI and albumin and impaired renal function were seen in
the lower Hb quartiles. The hemodynamic profile of the
patients in the lower quartiles were characterized by lower
blood pressure, but higher heart rate and pulmonary capil-
lary wedge pressure (Table 1). Greater impairment in
Abbreviations and Acronyms
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exercise capacity was demonstrated in HF patients with
lower Hb concentrations. Peak oxygen consumption
(PKVO2) on cardiopulmonary exercise testing was 12.8 
4.6, 12.4  4.5, 13.8  4.7 and 14.6  5.4 ml/kg per min
for quartiles 1, 2, 3 and 4, respectively, p  0.0001.
Relationship between Hb and mortality. There were 212
deaths by year one, and 360 deaths at five-year follow-up.
At one year, progressive HF death accounted for 98 deaths
(46%), while 89 deaths were sudden, 5 occurred secondary
to MI and 20 occurred from unknown or other causes. At
the end of one year, 247 of the 1,061 patients had received
heart transplants (126 urgent, Status 1; 148 nonurgent,
Status 2). At five-year follow-up, 405 patients received heart
transplants.
A low baseline Hb level in this cohort of advanced HF
patients proved to be a significant predictor of subsequent
mortality. The Hb level was significantly higher in patients
alive at one year compared to those who had died or had
undergone urgent transplant at one year. Table 2 details the
differences in baseline characteristics between survivors and
nonsurvivors at one year. On univariate Cox regression
analysis, each 1 g/dl decrease in Hb was associated with a
16% increased risk of death. Hemoglobin was similarly
predictive of mortality at five-year follow-up (data not
shown). Survival rates steadily declined as Hb quartile
decreased, as shown in the Kaplan-Meier survival curves for
the four Hb quartiles (Fig. 1). This stepwise trend was
preserved after the cohort was further subdivided by Hb
deciles, with no evidence of a U-shaped relationship (Fig. 2).
After adjusting for variables found to be significant
predictors of mortality on univariate analysis, Hb level
maintained its significant prognostic value. On multivariate
analysis, the risk of mortality increased by 13% for each
decrease by 1 g/dl in Hb (RR 1.131, CI 1.045 to 1.224).
Independent predictors of mortality, as determined by
multivariate analysis, are detailed in Table 3.
Kaplan-Meier survival curves were recalculated in clini-
cally significant subgroups to determine whether Hb main-
tained its prognostic value in these subsets of HF patients.
The association between low Hb and increased mortality
was preserved in subsets of patients with and without
coronary artery disease (CAD) as well as patients both older
and younger than the median age of 53 years (Fig. 3).
Because healthy women have lower Hb levels than healthy
men, we separated each gender group into quartiles before
recalculating survival curves. Hemoglobin was predictive of
mortality in both men and women, yet the association was
stronger in men (Fig. 3). The relationship between Hb and
mode of death was also investigated, revealing that Hb was
a significant predictor of progressive HF death (p 
0.00001), but not sudden death (p  0.73). After exclusion
of patients who received heart transplants, higher mortality
rates were still observed in patients with lower Hb (p 
0.005) (Fig. 3). On multivariate analysis, lower Hb re-
mained a significant predictor of increased mortality (RR
1.129, CI 1.018 to 1.251).
DISCUSSION
Major findings. Our study, which examined Hb level in a
large, well-characterized cohort of advanced HF patients,
demonstrates that Hb is significantly associated with symp-
toms, exercise capacity, and prognosis in patients with
advanced HF. Several findings deserve emphasis. First,
Table 1. Baseline Characteristics of the Study Cohort Divided by Hemoglobin Quartile
Hemoglobin (g/dl)
Quartile 1
(<12.3) (n  271)
Quartile 2
(12.3–13.6) (n  253)
Quartile 3
(13.7–14.8) (n  256)
Quartile 4
(>14.8) (n  281)
p Value
(ANOVA)
Age (yrs) 52  13 53  12 52  11 52  12 NS
Male (%) 65.3 68.4 82.8 91.1 0.0001
NYHA functional class IV (%) 75.3 68.0 56.7 59.1 0.0001
Ischemic etiology (%) 53.1 53.4 47.7 45.6 NS
Diabetes (%) 27.9 32.9 28.7 24.4 NS
Smokers (past or present) (%) 72.3 79.7 70.0 75.6 NS
Ejection fraction (%) 23  8 22  7 22  7 22  7 NS
LVEDD (mm) 70.7  10.2 71.2  10.9 73.5  11.3 73.0  9.7 0.008
PKVO2 (ml/kg/min) 12.8  4.6 12.4  4.5 13.8  4.7 14.6  5.4 0.0001
Body mass index (kg/m2) 24.9  4.8 25.3  5.4 26.7  5.0 26.3  6.5 0.0001
Sodium (mmol/l) 135  5 135  5 136  4 136  5 NS
Albumin (g/dl) 3.7  0.6 3.9  0.6 4.1  0.6 4.1  0.6 0.0001
Creatinine clearance (ml/min) 68  29 74  31 78  32 78  32 0.0001
Cholesterol (mg/dl) 167  55 176  55 186  58 181  53 0.0001
ACEI use (%) 64.6 71.5 73.4 73.3 NS
Heart transplants (%) 37.6 37.9 37.1 33.5 NS
HF time (months) 60.7  75.6 53.4  60.5 59.9  74.5 56.1  72.8 NS
Mean BP (mm Hg) 70  12 73  11 73  12 74  12 0.0001
Heart rate (beats/min) 90  17 88  16 87  15 86  17 0.02
PCW (mm Hg) 16  6 16  6 15  6 15  6 0.0001
Cardiac index (l/min/m2) 2.6  0.5 2.5  0.6 2.5  0.5 2.5  0.6 0.06
ACEI  angiotensin-converting enzyme inhibitor; ANOVA  analysis of variance; BP  blood pressure; HF  heart failure; LVEDD  left ventricular end diastolic
dimension; NS  p  0.05; NYHA  New York Heart Association; PCW  pulmonary capillary wedge pressure; PKVO2  peak oxygen consumption.
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although the relationship between anemia and adverse
outcomes has been described in patients with ESRD (7) and
patients with asymptomatic left ventricular dysfunction or
mild to moderate HF (2), our study extends this finding to
patients with advanced HF. The relationship between
anemia and mortality persists in subgroups based on gender,
age and HF etiology, and it is independent of other
established HF prognostic factors. Furthermore, based on
our analysis of Hb deciles, we have observed that mortality
decreases in linear fashion as Hb level increases, without
excess mortality at the highest Hb levels.
A second point of emphasis is the relatively mild degrees
of anemia associated with increased morbidity and mortal-
ity; significantly impaired survival was seen in women with
Hb 11.6 g/dl and men with Hb 12.6 g/dl, values that
may not be considered significant or associated with in-
creased risk in clinical practice. Third, patients with de-
creased Hb were characterized by an unfavorable hemody-
namic profile, worse symptoms of HF, as described by
NYHA functional class, and greater impairment in exercise
capacity, as quantified by PKVO2. Based on this analysis it
would be predicted that correction of anemia would be
associated with an improvement in exercise capacity of
approximately 2 ml/kg/min, which has previously been
shown to be clinically relevant (14). Interestingly, that was
the magnitude of improvement in exercise capacity recently
Table 2. Prediction of One-Year Mortality: Characteristics of Survivors and Nonsurvivors
Survivors
(n  739)
Nonsurvivors
(n  322)
p
Value* RR (95% CI)†
Hemoglobin (g/dl) 13.8  1.8 13.1  2.0 0.0001 0.861 (0.813–0.910)
Age (yrs) 52  11 52  12 NS —
Male (%) 77.8 75.5 NS —
NYHA functional class IV (%) 58.8 78.3 0.0001 2.466 (1.890–3.217)
Ejection fraction (%) 23  7 22  7 0.019 0.981 (0.965–0.997)
Severe MR (%) 29.2 37.2 0.005 1.395 (1.103–1.764)
Ischemic etiology (%) 47.1 56.2 0.004 1.384 (1.110–1.725)
PCW (mm Hg) 15  5 18  6 0.0001 1.081 (1.062–1.100)
PKVO2 (ml/kg/min) 13.9  5.0 11.9  4.3 0.0001 0.903 (0.860–0.948)
LVEDDI (mm/m2) 38.0  6.2 40.0  6.7 0.032 1.022 (1.003–1.042)
Hypertension (%) 45.9 43.8 NS —
Diabetes (%) 27.9 29.7 NS —
Body mass index (kg/m2) 25.9  5.7 25.6  5.2 NS —
Smokers (past or present) (%) 74.2 74.9 NS —
History of AF (%) 9.1 14.5 0.021 1.519 (1.061–2.173)
Sodium (mmol/l) 136  4 134  5 0.0001 0.917 (0.898–0.937)
Albumin (g/dl) 4.0  0.6 3.8  0.6 0.0001 0.586 (0.493–0.696)
Creatinine (mg/dl) 1.4  0.9 1.5  0.9 NS —
Blood urea nitrogen (mmol/l) 26  16 33  20 0.0001 1.014 (1.010–1.019)
Creatinine clearance (ml/min) 76  30 72  34 0.06 —
Cholesterol (mg/dl) 184  55 163  56 0.0001 0.993 (0.991–0.996)
ACEI (%) 77.0 56.2 0.0001 0.448 (0.359–0.559)
*p Value, likelihood ratio test, Cox regression analysis. †RR per unit increase for continuous variables and RR of characteristic
for categorical variables.
AF  atrial fibrillation; CI  confidence interval; LVEDDI  left ventricular end diastolic dimension index; MR  mitral
regurgitation; NYHA  New York Heart Association; RR  relative risk. Other abbreviations as in Table 1.
Figure 1. Kaplan-Meier survival analysis for the entire cohort by quartile of
hemoglobin (Hb) level. Figure 2. Mortality for the entire cohort by decile of hemoglobin level.
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observed in a small trial of 12 weeks of erythropoietin
therapy in patients with anemia and HF (10).
Epidemiologic evidence. Prior epidemiologic studies that
have included Hb or Hct in their analyses provide support-
ive evidence for the significant relationship between anemia,
HF and prognosis. Anemia was associated with an increased
risk of death or HF rehospitalization in California patients
hospitalized for HF between 1991 and 1992 (15). Further-
more, the Framingham Heart Study found Hct to be a
significant risk factor for increased HF incidence (16).
Although the present study describes a remarkable asso-
ciation between anemia and HF mortality, the pathophys-
iologic relationship between Hb and HF progression re-
quires further study. Hemoglobin may be a marker of poor
prognosis in HF or, conversely, it may play a causative role
in HF progression. Several potential explanations for the
association between low Hb and poor prognosis deserve
exploration.
Anemia of chronic disease. Increased levels of plasma
cytokines such as tumor necrosis factor in HF patients are
associated with higher NYHA functional class (17) and
increased HF mortality (18). Anemia in advanced HF may
be a marker of increased levels of circulating cytokines and
cytokine receptors. It is known that anemia commonly seen
in chronic inflammatory states, such as some infections,
neoplasm and rheumatologic conditions, is mediated by
inflammatory cytokines such as tumor necrosis factor,
interleukin-1 and the interferons (19). It may be that the
anemia in HF is similar to that seen in other chronic
diseases and is likewise mediated by elevated circulating
cytokines. As with anemia of other chronic disease states,
increased erythropoietin levels have been found in patients
with chronic heart failure (20).
Malnutrition. In our study, patients in the lower Hb
quartiles were characterized by markers of malnutrition,
such as lower levels of albumin and lower BMI (Table 1).
Table 3. One-Year Mortality Rates of the Cohort by Hemoglobin Quartile
Hemoglobin (mg/dl)
Quartile 1
(<12.3)
Quartile 2
(12.3–13.6)
Quartile 3
(13.7–14.8)
Quartile 4
(>14.8)
Number 271 253 256 281
Death or urgent transplantation 109 82 66 65
Mortality (death or UT) 44.4% 36.1% 28.6% 25.6%
Age and gender-adjusted RR 2.015 1.490 1.099 1.0
(95% CI) (1.482–2.741) (1.076–2.063) (0.779–1.549)
Multivariate RR* 1.861 1.369 1.298 1.0
(95% CI) (1.215–2.852) (0.871–2.145) (0.826–2.039)
*Adjusted for age, gender, body mass index, ejection fraction, left ventricular end diastolic dimension, history of hypertension,
diabetes, and smoking, serum sodium, albumin, creatinine and heart failure etiology.
UT  urgent transplantation. Other abbreviations as in Table 2.
Figure 3. Mortality by hemoglobin quartile (Q) for the total cohort compared to subgroups of men (Q1 12.6; Q2 12.6–13.9; Q3 14.0–15.0; Q4
15.0 g/dl) and women (Q1 11.6; Q2 11.6–12.6; Q3 12.7–13.8; Q4 13.8 g/dl), patients with ischemic and nonischemic cardiomyopathy (CMY), and
excluding patients who underwent urgent or elective status transplantation.
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Malnutrition is a common causative factor in the develop-
ment of anemia in non-HF populations, such as the elderly
(21). It is possible that the poor prognosis of anemia in HF
stems from malnutrition due to cardiac cachexia, a catabolic
state seen in advanced HF and associated with increased HF
mortality (22). However, Hb was predictive of mortality
independent of BMI and albumin levels.
Hemodilution. Low Hb may be a marker of volume
overload in poorly compensated, high-risk HF patients.
Previous studies have demonstrated that decreased Hb or
Hct in HF is reflective of plasma volume expansion and not
necessarily indicative of decreased red blood cell volume
(23). Because Hb was predictive of mortality independent of
pulmonary capillary wedge pressure after hemodynamically
guided diuresis, hemodilution alone cannot fully account for
these findings.
Anemia and ischemia. Although it has been shown that
the resting, healthy human heart can withstand acute, severe
anemia without sustaining myocardial ischemia (24), the
presence of CAD may significantly impair the heart’s ability
to tolerate low levels of Hb (25). A recent observational
study showed reduction in 30-day mortality in patients with
Hct 33% who received blood transfusion during hospital-
ization for MI compared to those who were not transfused
(26). Anemia in HF patients may predispose to myocardial
ischemia, repetitive stunning, apoptosis, and necrosis, thus
contributing to the progression of ventricular dilation and
clinical HF.
Renal insufficiency. The kidney and its related hormonal
mechanisms play a fundamental role in the pathophysiology
of HF. Impaired renal function is associated with both
anemia and worse prognosis in patients with HF. Although
lower Hb was associated with higher blood urea nitrogen
and creatinine and lower creatinine clearance, the increased
mortality risk seen remained after adjustment for renal
function and other HF prognostic factors. Similarly, in the
SOLVD analysis the increased mortality risk with anemia in
HF was independent of renal function impairment (2). It
should be noted, however, that in a randomized clinical trial
involving patients with ESRD and HF, normalization of
Hct (42%) with erythropoietin and intravenous (IV) iron
dextran compared to maintaining lower Hct levels (30%)
was associated with a trend for increased nonfatal MIs and
mortality (RR 1.3; 95% CI 0.9 to 1.9, p  NS) (27).
Study limitations. Our study is retrospective and examines
a selected population of HF patients with advanced disease
referred for transplant evaluation. Hemoglobin levels were
assessed at a single point in time, and thus we cannot
comment on the importance in change in Hb over time.
Treatment of anemia with transfusion or other medications
during the time course of the study is also not documented
or included in the analysis, though it was not routine to treat
these patients with transfusions, iron or erythropoietin.
Data on the use of beta-blockers or addition of medicines
after the time of initial presentation are not included in the
analysis. We also do not have data on cytokine or erythro-
poietin levels, or direct measures of plasma volume or red
blood cell mass, information that would help in understand-
ing the pathophysiologic role of anemia in HF progression.
Conclusions. Lower Hb is associated with greater func-
tional impairment, worse exercise capacity, and increased
mortality in this cohort of advanced HF patients of multiple
etiologies. Further studies aimed at understanding the
interaction between Hb and HF progression are needed.
Initial studies suggest that treatment of anemia is beneficial
in HF (8). Additional randomized, placebo-controlled stud-
ies are warranted to test the hypothesis that correction of
anemia improves symptoms and exercise capacity in ad-
vanced HF and also to determine whether treatment of
anemia has an impact on HF survival.
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